Daily Cosmetic Research Analysis
Three impactful studies reshape our understanding of cosmetics in health: a Science Advances paper shows personal care products suppress the human oxidation field (OH radicals) with implications for indoor air chemistry, an ALTEX case study demonstrates next-generation non-animal risk assessment for the sunscreen filter benzophenone-4, and a randomized split-face trial finds platelet-rich plasma via microneedling outperforms microinjection for melasma. Together they advance exposure science, reg
Summary
Three impactful studies reshape our understanding of cosmetics in health: a Science Advances paper shows personal care products suppress the human oxidation field (OH radicals) with implications for indoor air chemistry, an ALTEX case study demonstrates next-generation non-animal risk assessment for the sunscreen filter benzophenone-4, and a randomized split-face trial finds platelet-rich plasma via microneedling outperforms microinjection for melasma. Together they advance exposure science, regulatory toxicology, and aesthetic dermatology.
Research Themes
- Cosmetic product exposure and indoor chemistry
- Non-animal regulatory toxicology for sunscreens
- Optimization of aesthetic dermatology interventions
Selected Articles
1. Personal care products disrupt the human oxidation field.
Using real-world personal care products, the authors show that lotions reduce formation of the OH precursor 6-MHO and fragrance ethanol acts as a major OH sink, suppressing the human oxidation field. Multiphase kinetic and CFD modeling explain how reactive species evolve indoors, highlighting implications for indoor air chemistry and human exposures.
Impact: This is a rigorous mechanistic elucidation of how personal care products modulate near-skin oxidative chemistry, a previously underappreciated pathway influencing indoor exposures and potentially health.
Clinical Implications: While not a clinical trial, the findings inform public health counseling and product formulation choices (e.g., ethanol-rich fragrances) and support ventilation strategies to mitigate potential oxidative chemistry perturbations in indoor environments.
Key Findings
- Body lotion application reduced formation of 6-methyl-5-hepten-2-one, a key precursor for OH generation near skin.
- Volatile ingredients in many PCPs increased gas-phase OH loss; ethanol in fragrances acted as a dominant OH sink despite terpene content.
- Combined multiphase chemical kinetics and CFD modeling reproduced indoor concentration dynamics of reactive species and suppression of the human oxidation field.
Methodological Strengths
- Integration of multiphase chemical kinetics with computational fluid dynamics for mechanistic, spatially resolved insights
- Use of real consumer personal care products to enhance external validity
Limitations
- No direct clinical or health outcomes were measured
- Tested a limited set of products; results may vary with different formulations and individual emission profiles
Future Directions: Quantify health-relevant endpoints and evaluate broader product classes and ventilation scenarios to translate mechanistic insights into exposure guidelines.
People generate hydroxyl radicals (OH) in the presence of ozone via the ozonolysis of skin-emitted alkenes. In this study, we found that the application of personal care products (PCPs) including fragrances and body lotions suppresses the human oxidation field. Body lotion hampers the generation of 6-methyl-5-hepten-2-one, a key OH precursor, while many volatile ingredients of PCPs enhance OH loss in the gas phase. Although fragrances contain terpenes capable of generating OH through ozonolysis, the much larger amount of ethanol solvent acts as a large OH sink. We combined a multiphase chemical kinetic model and a computational fluid dynamics model to demonstrate how the concentrations of the reactive components develop in the indoor environment. These findings have implications for the indoor chemistry of occupied spaces and human health.
2. Making safety decisions for a sunscreen active ingredient using next-generation risk assessment: Benzophenone-4 case study.
A comprehensive NGRA for BP-4 in lotion combined PBK modeling with multiple in vitro bioactivity platforms to derive bioactivity exposure ratios, indicating low systemic exposure and that most biological responses occur above predicted consumer exposure. Gene-level transcriptomic signals at low PoDs likely represent adaptive changes rather than adverse effects.
Impact: Demonstrates a decision-ready, animal-free safety assessment framework for a widely used sunscreen filter, directly addressing regulatory needs and accelerating ethical, efficient risk evaluations.
Clinical Implications: Supports confidence in consumer safety of BP-4 at realistic exposures, informs product formulation and labeling, and encourages adoption of NGRA approaches that could streamline regulatory review without animal testing.
Key Findings
- PBK modeling predicted low systemic exposure to BP-4 (plasma Cmax 95th percentile 1.27 μM; liver 0.32 μM; kidney 0.44 μM).
- Bioactivity exposure ratios were mostly >11 across platforms; lowest PoDs were gene-level signals (BER 3.3–4.3) likely reflecting adaptive, not adverse, responses.
- NGRA integrating in silico and in vitro methods can inform safety decisions for sunscreen actives without animal data.
Methodological Strengths
- Physiologically based kinetic modeling anchored by exposure characterization
- Multi-platform in vitro bioactivity assessment enabling cross-validation of PoDs
Limitations
- Relies on modeling and in vitro systems; lacks confirmatory human biomonitoring data in this study
- Interpretation of transcriptomic PoDs as adaptive requires further corroboration
Future Directions: Pair NGRA with targeted human biomonitoring and aggregate exposure modeling across products to refine margins of safety and generalize the framework to other UV filters.
A next generation risk assessment was carried out to evaluate the safety of benzophenone-4 (BP-4), a UV filter present at 5% in a body lotion, to compare a non-animal approach with a traditional safety assessment based on historical animal data. Exposure characterization indicated that BP-4 is poorly absorbed through the skin, poorly metabolized by the liver, a substrate of influx and efflux transporters, and excreted by the kidney. The resulting physiologically-based kinetic model predicted an upper bound (95th percentile) plasma Cmax of 1.27 μM, and liver and kidney concentrations of 0.32 μM and 0.44 μM, respectively. To characterize bioactivity, in silico and in vitro new approach methodologies were used. Points of departure (PoDs) were derived from four bioactivity platforms, including in vitro pharmacological profiling, CALUX assays, high-throughput transcriptomics, and a cell stress panel. By dividing the in vitro PoDs (PoDNAM) from these assays by the 95th percentile plasma Cmax value, bioactivity exposure ratios (BERs) were calculated. The lowest PoD was from a single gene expression change, and the highest PoD from phenotypic biomarkers using a primary renal cell model. Most BERs were above 11, except for those from gene-level PoDNAM in HepG2 and MCF-7 cells, which were 3.3 and 4.3. These lowest PoDNAM values are linked to gene transcription changes and are likely indicative of adaptive biological activity rather than adverse health effects. This work demonstrates the usefulness of next generation risk assessment in addressing pressing relevant regulatory questions without using animals.
3. Efficacy of Platelet Rich Plasma Therapy in Melasma Using Microinjections and Microneedling Techniques.
In a prospective randomized split-face trial of 62 patients, PRP delivered by microneedling produced significantly greater improvements in melasma severity (MASI) than microinjection (p<0.001), with no noteworthy adverse effects. Patient- and physician-reported outcomes aligned with objective scores.
Impact: Provides randomized comparative evidence guiding how PRP should be delivered for melasma, favoring microneedling over microinjection.
Clinical Implications: For patients considering PRP for melasma, microneedling-based delivery should be preferred due to superior efficacy and acceptable safety; clinics can incorporate standardized MASI-based monitoring.
Key Findings
- Randomized split-face design (n=62) showed microneedling PRP significantly outperformed microinjection in reducing MASI (p<0.001).
- Greater proportions of substantial (>50% and >75%) improvement were observed with microneedling versus microinjection.
- No noteworthy adverse effects were reported across either delivery method.
Methodological Strengths
- Prospective randomized split-face design controlling for inter-individual variability
- Use of standardized outcomes (modified MASI, physician and patient global assessments)
Limitations
- Single-center study with modest sample size
- Short follow-up; durability of response beyond the study period is unclear
Future Directions: Conduct multicenter, blinded trials with longer follow-up to assess durability, optimize PRP protocols (e.g., concentration, session number), and compare with standard topical or energy-based therapies.
INTRODUCTION: Melasma is a long-term acquired disorder characterized by symmetrical darkening in facial regions exposed to sunlight. Although some risk factors have been identified, the etiology remains unclear, and interventions frequently do not totally improve outcomes. AIM: It compares the efficacy and side effects of platelet-rich plasma therapy administered by microneedling versus microinjection to detect any difference in the delivery methods, treatment outcomes, and safety profiles. METHODS: In this prospective, single-center, randomized split-face research, 62 patients' melasma was treated with PRP therapy using microneedling versus microinjection. Microneedling and microinjection were used to apply PRP to the face's two sides. Photographs were obtained before therapy, and the modified Melasma Area and Severity Index (MASI), Physician Global Assessment, and Patient Global Assessment were used for monthly follow-up evaluation. In order to compare safety and efficacy, adverse events were recorded and statistical analysis was performed. RESULTS: A significantly significant difference (p < 0.001) was observed in the mean change in MASI score between microinjection and microneedling. The microneedling group showed a 73.33% improvement while the microinjection group had an 18.33% improvement, both of which were greater than 50%. The microneedling group showed a 46.67% improvement and the microinjection group had a 5% improvement of over 75%. There were no noteworthy negative effects observed. CONCLUSION: PRP therapy with microneedling is superior to microinjection in treating melasma; patients who receive microneedling show noticeably better improvement.